神经基因公司

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
  TipRanks · 2026/6/11
• 评级变动
  Guggenheim Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $69
  \u5e02\u573a\u8d44\u8baf · 2026/4/28
• 评级变动
  William Blair Maintains Neurogene(NGNE.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/8
• 评级变动
  Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/21
• 评级变动
  Guggenheim Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $69
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $180
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 评级变动
  H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/7/11
• A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $166
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Rodman & Renshaw Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/9

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。